Abstract
The locomotor effects of (−)- and (+)-OSU6162 were evaluated in ‘low activity’ animals (reserpinized mice and habituated rats) and ‘high activity’ animals (drug-naive mice and non-habituated rats). Both enantiomers of OSU6162 had dual effects on behavior, stimulating locomotor activity in ‘low activity’ animals and inhibiting locomotor activity in ‘high activity’ animals. There were also certain differences between the two enantiomers in their behavioral profiles. The stimulatory effects of both enantiomers in reserpinized mice were blocked by the 5-HT2A selective antagonist M100907, but not by the D2-selective antagonists haloperidol or raclopride, or by the D1-selective antagonists SCH23390 or SCH39166. The stimulatory effect in mice was more pronounced for (+)- than for (−)-OSU6162. In drug-naive mice, both enantiomers of OSU6162 produced head twitches, albeit to a much lesser extent than DOI, and both enantiomers inhibited DOI-induced head twitches, the (−)-form more effectively so than the (+)-form. These results suggest that (−)- and (+)-OSU6162 are partial agonists on 5-HT2A receptors and that the (+)-form has a higher intrinsic activity than the (−)-form. At high doses, both enantiomers inhibited locomotor activity in drug-naive mice, with (−)-OSU6162 being more potent than (+)-OSU6162. Similarly, in high-active rats, both enantiomers inhibited locomotor activity, with the (−)-enantiomer being more potent than the (+)-enantiomer. Conversely, in habituated rats, both enantiomers stimulated locomotor activity, and here, as opposed to the case in low-active mice, (−)-OSU6162 was more effective than (+)-OSU6162. The stimulatory effects in habituated rats of both enantiomers could be antagonized with either haloperidol or M100907. Overall, these results indicate that the dual effects on behavior of (−)- and (+)-OSU6162 are mediated through D2 and 5-HT2A receptors, consistent with their in vitro functional selectivity profiles (see Burstein et al., accompanying paper). Thus, both enantiomers of OSU6162 seem to act as stabilizers not only on dopaminergic, but also on serotonergic brain signaling. These discoveries have important implications for the potential clinical utility of both compounds, as well as for several of their congeners.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Carlsson ML, Carlsson A, Nilsson M (2004) Schizophrenia: from dopamine to glutamate and back. Curr Med Chem 11(3):267–277
Dyhring T, Nielsen EØ, Sonesson C, Pettersson F, Karlsson J, Svensson P, Christophersen P, Waters N (2010) The dopaminergic stabilizers pridopidine (ACR16) and (−)-OSU6162 display dopamine D(2) receptor antagonism and fast receptor dissociation properties. Eur J Pharmacol 628(1–3):19–26
Ekesbo A, Andrén PE, Gunne LM, Tedroff J (1997) (−)-OSU 6162 inhibits levodopa-induced dyskinesias in a monkey model of Parkinson’s disease. Neuroreport 8(11):2567–2570
Ekesbo A, Torstenson R, Hartvig P, Carlsson A, Sonesson C, Waters N, Tedroff J, Långström B (1999) Effects of the substituted (S)-3-phenylpiperidine (−)-OSU6162 on PET measurements of [11C]SCH23390 and [11C]raclopride binding in primate brains. Neuropharmacology 38(3):331–338
Gefvert O, Lindström LH, Dahlbäck O, Sonesson C, Waters N, Carlsson A, Tedroff J (2000) (−)-OSU6162 induces a rapid onset of antipsychotic effect after a single dose. A double-blind placebo-controlled pilot study. Scandinavian Society for Psychopharmacology 41st annual meeting, Copenhagen, Denmark. Nord J Psychiatry 54:93–94
Grubbs FE (1969) Procedures for detecting outlying observations in samples. Technometrics 11(1):1–21
Kara E, Lin H, Svensson K, Johansson AM, Strange PG (2010) Analysis of the actions of the novel dopamine receptor-directed compounds (S)-OSU6162 and ACR16 at the D2 dopamine receptor. Br J Pharmacol 161(6):1343–1350
Lahti RA, Tamminga CA, Carlsson A (2007) Stimulating and inhibitory effects of the dopamine ‘‘stabilizer’’ (−)-OSU6162 on dopamine D(2) receptor function in vitro. J Neural Transm 114(9):1143–1146
Lundberg T, Tedroff J, Waters N, Sonesson C, Carlsson A, Hagström P, Lindström LH, Gefvert O (2002) Safety of early clinical experience with (−)-OSU6162, a dopaminergic stabilizer with antipsychotic properties. In: SCNP 43rd Annual and 2nd Mediterranean Meeting, Juan-les-Pins, France. Nord J Psychiatry 56:24
Moreno FA, Wiegand CB, Taitano EK, Delgado PL (2006) Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive–compulsive disorder. J Clin Psychiatry 67(11):1735–1740
Natesan S, Svensson KA, Reckless GE, Nobrega JN, Barlow KB, Johansson AM, Kapur S (2006) The dopamine stabilizers (S)-(−)-(3-methanesulfonyl-phenyl)-1-propyl-piperidine [(−)-OSU6162] and 4-(3-methanesulfonylphenyl)-1-propyl-piperidine (ACR16) show high in vivo D2 receptor occupancy, antipsychotic-like efficacy, and low potential for motor side effects in the rat. J Pharmacol Exp Ther 318(2):810–818
Rodriguez CA, Azie NE, Adams G et al (2004) Single oral dose safety, tolerability, and pharmacokinetics of PNU-96391 in healthy volunteers. J Clin Pharmacol 44:276–283
Rung JP, Rung E, Helgeson L, Johansson AM, Svensson K, Carlsson A, Carlsson ML (2008) Effects of (−)-OSU6162 and ACR16 on motor activity in rats, indicating a unique mechanism of dopaminergic stabilization. J Neural Transm 115(6):899–908
Rung JP, Rung E, Johansson AM, Svensson K, Carlsson A, Carlsson ML (2011) Effects of the dopamine stabilizers (S)-(−)-OSU6162 and ACR16 on prolactin secretion in drug-naive and monoamine-depleted rats. Naunyn Schmiedebergs Arch Pharmacol 384:39–45
Seeman P, Guan HC (2007) Dopamine partial agonist action of (−)OSU6162 is consistent with dopamine hyperactivity in psychosis. Eur J Pharmacol 557(2–3):151–153
Sonesson C, Lin CH, Hansson L, Waters N, Svensson K, Carlsson A, Smith MW, Wikström H (1994) Substituted (S)-phenylpiperidines and rigid congeners as preferential dopamine autoreceptor antagonists: synthesis and structure–activity relationships. J Med Chem 37(17):2735–2753
Sonesson C (1995) Arylpiperidine and arylpyrrolidine derivatives with potential antipsychotic efficacy. Thesis, ISBN 91-554-3453-3
Svensson KA, Falcone JF, Johansson AM, Perry KW et al (2009) The actions of the dopamine stabilizer ACR16, but not (−)-OSU6162, in behavioral and neurochemical assays are not dependent on the presence of functional dopamine D2 receptors. Presented at the 39th Annual Meeting, Society for Neuroscience. Chicago, October
Tedroff J, Ekesbo A, Sonesson C, Waters N, Carlsson A (1999) Longlasting improvement following (−)-OSU6162 in a patient with Huntington’s disease. Neurology 53(7):1605–1606
Acknowledgments
This research was supported by Västra Götalandsregionen, grants from the state (of Sweden) under the LUA/ALF agreement, the Arvid Carlsson Foundation, the Foundation for Neuropharmacological Research and Education and Wilhelm och Martina Lundgrens vetenskapsfond.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Carlsson, M.L., Burstein, E.S., Kloberg, A. et al. I. In vivo evidence for partial agonist effects of (−)-OSU6162 and (+)-OSU6162 on 5-HT2A serotonin receptors. J Neural Transm 118, 1511–1522 (2011). https://doi.org/10.1007/s00702-011-0704-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00702-011-0704-8